TP53 and acute myeloid leukemia: In addition to demonstrating that normal myeloid blasts typically have lower CD9 expression compared to most leukemic blasts (with the exception of TP53-mutated AML, although that cohort included only 6 cases), we further subcategorized AMLs and analyzed CD9 expression across various AML subtypes.